Paul A. Gurbel
Paul A. Gurbel works as the Director of the Sinai Center for Thrombosis Research at the Sinai Hospital of Baltimore, Baltimore, Md, USA, and Associate Professor of medicine with the Johns Hopkins University School of Medicine in Baltimore, Md, USA. His research laboratory is primarily focused on determining the antiplatelet effects of current and new agents and the relation of platelet reactivity to ischemic event occurrence. His laboratory was the first to demonstrate the relation between high platelet reactivity to adenosine phosphate and ischemic event occurrence in the PCI population. These critical observations served as the rationale for the development of new P2Y12 inhibitors. He holds patents in the fields of interventional cardiology and antithrombotic therapy. Dr. Gurbel earned his medical degree in the School of Medicine, University of Maryland, College Park, Md, USA, and completed an Internship and Residency in internal medicine at Duke University Medical Center in Durham, , NC, USA. Dr. Gurbel then completed a Fellowship in pulmonary and critical care at Johns Hopkins University, followed by Fellowships in cardiovascular disease and interventional cardiology as well as a Chief Residency in internal medicine at Duke. He is board certified in internal medicine, cardiovascular disease, and interventional cardiology by the American Board of Internal Medicine. Dr. Gurbel serves on the editorial boards for Clinical Geriatrics and Journal of Medicine. In addition to book chapters and monographs, he has authored over 200 articles in peer-reviewed journals, most recently including The American Journal of Cardiology, JAMA, Platelets, Circulation, and Journal of the American College of Cardiology.
Biography Updated on 2 January 2013